-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27

Benzinga·11/06/2026 16:54:02
Listen to the news
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $25 to $27.